SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Tham Emma) ;lar1:(gu)"

Search: WFRF:(Tham Emma) > University of Gothenburg

  • Result 1-3 of 3
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Löfström, Emma, et al. (author)
  • Dynamics of IgG-avidity and antibody levels after Covid-19
  • 2021
  • In: Journal of Clinical Virology. - Amsterdam : Elsevier. - 1386-6532 .- 1873-5967. ; 144
  • Journal article (peer-reviewed)abstract
    • Background: A potentially important aspect of the humoral immune response to Covid-19 is avidity, the overall binding strength between antibody and antigen. As low avidity is associated with a risk of re- infection in several viral infections, avidity might be of value to predict risk for reinfection with covid-19. Objectives: The purpose of this study was to describe the maturation of IgG avidity and the antibody-levels over time in patients with PCR-confirmed non-severe covid-19. Study design: Prospective longitudinal cohort study including patients with RT-PCR confirmed covid-19. Blood samples were drawn 1, 3 and 6 months after infection. Antibody levels and IgG-avidity were analysed. Results: The majority had detectable s- and n-antibodies (88,1%, 89,1%, N = 75). The level of total n-antibodies significantly increased from 1 to 3 months (median value 28,3 vs 39,3 s/co, p<0.001) and significantly decreased from 3 to 6 months (median value 39,3 vs 17,1 s/co, p<0.001). A significant decrease in the IgG anti-spike levels (median value 37,6, 24,1 and 18,2 RU/ml, p<0.001) as well as a significant increase in the IgG-avidity index (median values 51,6, 66,0 and 71,0%, p<0.001) were seen from 1 to 3 to 6 months. Conclusion: We found a significant ongoing increase in avidity maturation after Covid-19 whilst the levels of antibodies were declining, suggesting a possible aspect of long-term immunity. © 2021 The Authors. Published by Elsevier B.V.
  •  
2.
  • Omran, Meis, et al. (author)
  • Whole-Body MRI Surveillance : Baseline Findings in the Swedish Multicentre Hereditary TP53-Related Cancer Syndrome Study (SWEP53)
  • 2022
  • In: Cancers. - : MDPI. - 2072-6694. ; 14:2
  • Journal article (peer-reviewed)abstract
    • A surveillance strategy of the heritable TP53-related cancer syndrome (hTP53rc), commonly referred to as the Li–Fraumeni syndrome (LFS), is studied in a prospective observational nationwide multi-centre study in Sweden (SWEP53). The aim of this sub-study is to evaluate whole-body MRI (WB-MRI) regarding the rate of malignant, indeterminate, and benign imaging findings and the associated further workup generated by the baseline examination. Individuals with hTP53rc were enrolled in a surveillance program including annual whole-body MRI (WB-MRI), brain-MRI, and in female carriers, dedicated breast MRI. A total of 68 adults ≥18 years old have been enrolled to date. Of these, 61 fulfilled the inclusion criteria for the baseline MRI scan. In total, 42 showed a normal scan, while 19 (31%) needed further workup, of whom three individuals (3/19 = 16%) were diagnosed with asymptomatic malignant tumours (thyroid cancer, disseminated upper GI cancer, and liver metastasis from a previous breast cancer). Forty-three participants were women, of whom 21 had performed risk-reducing mastectomy prior to inclusion. The remaining were monitored with breast MRI, and no breast tumours were detected on baseline MRI. WB-MRI has the potential to identify asymptomatic tumours in individuals with hTP53rc syndrome. The challenge is to adequately and efficiently investigate all indeterminate findings. Thus, a multidisciplinary team should be considered in surveillance programs for individuals with hTP53rc syndrome.
  •  
3.
  • Tesi, Bianca, et al. (author)
  • Diagnostic yield and clinical impact of germline sequencing in children with CNS and extracranial solid tumors : a nationwide, prospective Swedish study
  • 2024
  • In: The Lancet Regional Health. - : Elsevier. - 2666-7762. ; 39
  • Journal article (peer-reviewed)abstract
    • BackgroundChildhood cancer predisposition (ChiCaP) syndromes are increasingly recognized as contributing factors to childhood cancer development. Yet, due to variable availability of germline testing, many children with ChiCaP might go undetected today. We report results from the nationwide and prospective ChiCaP study that investigated diagnostic yield and clinical impact of integrating germline whole-genome sequencing (gWGS) with tumor sequencing and systematic phenotyping in children with solid tumors.MethodsgWGS was performed in 309 children at diagnosis of CNS (n = 123, 40%) or extracranial (n = 186, 60%) solid tumors and analyzed for disease-causing variants in 189 known cancer predisposing genes. Tumor sequencing data were available for 74% (227/309) of patients. In addition, a standardized clinical assessment for underlying predisposition was performed in 95% (293/309) of patients.FindingsThe prevalence of ChiCaP diagnoses was 11% (35/309), of which 69% (24/35) were unknown at inclusion (diagnostic yield 8%, 24/298). A second-hit and/or relevant mutational signature was observed in 19/21 (90%) tumors with informative data. ChiCaP diagnoses were more prevalent among patients with retinoblastomas (50%, 6/12) and high-grade astrocytomas (37%, 6/16), and in those with non-cancer related features (23%, 20/88), and ≥2 positive ChiCaP criteria (28%, 22/79). ChiCaP diagnoses were autosomal dominant in 80% (28/35) of patients, yet confirmed de novo in 64% (18/28). The 35 ChiCaP findings resulted in tailored surveillance (86%, 30/35) and treatment recommendations (31%, 11/35).InterpretationOverall, our results demonstrate that systematic phenotyping, combined with genomics-based diagnostics of ChiCaP in children with solid tumors is feasible in large-scale clinical practice and critically guides personalized care in a sizable proportion of patients.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-3 of 3
Type of publication
journal article (3)
Type of content
peer-reviewed (3)
Author/Editor
Rosén, Anna, 1975- (2)
Tham, Emma (2)
Kuchinskaya, Ekateri ... (2)
Herold, Nikolas (1)
Ahlström, Håkan, 195 ... (1)
Abel, Frida, 1974 (1)
show more...
Kogner, Per (1)
Martinsson, Tommy, 1 ... (1)
Brandberg, Yvonne (1)
Leonhardt, Henrik, 1 ... (1)
Tettamanti, Giorgio (1)
Mertens, Fredrik (1)
Rosenquist, Richard (1)
Lingman, Markus, 197 ... (1)
Tham, Johan (1)
Nygren, Jens M., 197 ... (1)
Lundgren, Claudia, 1 ... (1)
van Westen, Danielle (1)
Taylan, Fulya (1)
Wirta, Valtteri (1)
Persson, Fredrik (1)
Löfström, Emma (1)
Undén, Johan (1)
Pronk, Cornelis Jan (1)
Ljungman, Gustaf, 19 ... (1)
Sandgren, Johanna (1)
Blomqvist, Lennart (1)
Gisselsson, David (1)
Berg, Johanna (1)
Stenmark-Askmalm, Ma ... (1)
Lähteenmäki, Päivi (1)
Noren-Nyström, Ulrik ... (1)
Arvidsson, Linda (1)
Nordgren, Ann, 1964 (1)
Tesi, Bianca (1)
Pal, Niklas (1)
Díaz de Ståhl, Teres ... (1)
Vogt, Hartmut (1)
Giraud, Geraldine (1)
Borssén, Magnus (1)
Fransson, Susanne (1)
Lagerstedt-Robinson, ... (1)
Sabel, Magnus, 1966 (1)
Samuelsson, Sofie (1)
Nordling, Margareta (1)
Hallbeck, Anna-Lotta (1)
Ek, Torben, 1963 (1)
Paulsson-Karlsson, Y ... (1)
Nyman, Per (1)
Fili, Maria (1)
show less...
University
Lund University (3)
Umeå University (2)
Uppsala University (2)
Linköping University (2)
Karolinska Institutet (2)
show more...
Royal Institute of Technology (1)
Halmstad University (1)
show less...
Language
English (3)
Research subject (UKÄ/SCB)
Medical and Health Sciences (3)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view